Journal of Medical Genetics and Clinical Biology
Homepage : https://journal.antispublisher.id/index.php/JMGCB
Email : admin@antispublisher.com

e-ISSN : 3032-1085
JMGCB, Vol. 2, No. 1, January 2025
Page 37-52

The Impact of Inflammation on Diabetes: Physiological Pathways and Clinical Outcomes

Rawaa Sahib Abdulhasan
University of Thi-Qar, Iraq

DOI : https://doi.org/10.61796/jmgcb.v2i1.1076

Sections Info

Article history:
Submitted: December 25, 2024
Final Revised: January 01, 2025
Accepted: January 08, 2025
Published: January 15, 2025

Keywords:
Inflammation
Diabetes
Insulin resistance
Cytokines
Oxidative stress
Clinical outcomes

ABSTRACT

Objective: *To investigate the role of inflammation in diabetes, its impact on physiological pathways, clinical outcomes, and potential therapeutic strategies.* ***Methods:*** *A comprehensive review of existing literature was conducted to elucidate the mechanisms linking inflammation with diabetes and evaluate the clinical implications and emerging therapeutic approaches.* ***Results:*** *Inflammation significantly contributes to the onset and progression of diabetes. In type 2 diabetes, chronic low-grade inflammation, driven by pro-inflammatory cytokines like TNF-a and IL-6, disrupts insulin signaling, leading to insulin resistance. Oxidative stress induced by inflammation further deteriorates beta-cell function, impairing insulin production. In type 1 diabetes, autoimmune-induced inflammation destroys pancreatic beta cells, triggering hyperglycemia. Clinically, elevated markers such as CRP are correlated with complications like cardiovascular diseases, neuropathy, and nephropathy. Anti-inflammatory therapies show promise in improving glycemic control and reducing complications.* ***Novelty:*** *This study highlights the intricate link between inflammation and diabetes, emphasizing novel therapeutic strategies targeting inflammation to address glycemic control and mitigate disease-related complications. Understanding these mechanisms is essential for combating the global diabetes epidemic.*

INTRODUCTION

Diabetes is a term used to describe a metabolic disorder that causes the body to have abnormally high sugar levels in the blood. Prolonged high blood sugar levels in the body can lead to several health problems, some of which can be life-threatening. Inflammatory pathways are central to the development and progression of diabetes, and individuals presenting with systemic inflammation are frequently affected by subtypes of diabetes, particularly insulin resistance and type 2 diabetes. A better understanding of the underlying pathophysiology is essential to develop more effective clinical treatment or management to help reduce the burden on diabetic patients. In this essay, the aim is to provide a review of the complex relationship between inflammation and diabetes by exploring potential pathways related to pathological inflammation and subsequent metabolic disturbances [1], [2].

Inflammation has a dual effect and can be either beneficial or harmful. Understanding how inflammation can be reduced or resolved is critical for treating chronic conditions such as diabetes. The goals of this essay are to: examine established and emerging pathophysiological pathways in diabetes, which may be driven by inflammation; describe possible pathways of how inflammation and subclinically elevated high-sensitivity CRP can contribute to cardiovascular risk; assess physiological

pathways where diabetes can affect inflammation. The overall aim is to better understand how chronic inflammation associates with diabetes and affects clinical outcomes and response to therapies in order to improve care for diabetic patients. Inflammation, as a modifiable indicator in diabetes, may provide important reassurance regarding cardiovascular and cardiovascular-related risk in the clinical context [3], [4].

RESEARCH METHOD

1. **Literature Review**
    a. Relevant scientific articles, clinical studies, and experimental research were identified using databases like PubMed and Google Scholar, focusing on inflammation, diabetes, and associated biomarkers.
    b. Search terms included keywords such as "inflammation," "diabetes," "insulin resistance," and "cytokines."
2. **Data Analysis**
    a. Data were categorized into major themes such as inflammatory markers, physiological pathways, insulin resistance, and inflammatory mediators.
    b. Patterns and trends were compared and analyzed.
3. **Biomarker Assessment**
    a. Biomarkers like C-reactive protein (CRP), interleukins, and tumor necrosis factor-alpha (TNF-α) were examined for their roles in glucose metabolism and insulin resistance.
4. **Experimental Integration**
    a. Findings from experimental studies were integrated to support hypotheses regarding inflammation-mediated diabetes progression.
5. **Ethical Considerations**
    a. As no primary data collection was conducted, all secondary data sources were appropriately cited and acknowledged.

RESULTS AND DISCUSSION

1. The Role of Inflammation in the Pathogenesis of Diabetes

Inflammation is a central common cause of diabetes that mediates various metabolic disturbances, including metabolic syndrome, impaired beta-cell function, inadequate insulin production, and hepatic insulin resistance. Metabolism-induced inflammation has been recognized as a causative factor of type 2 diabetes and gestational diabetes. Insulin resistance is defined as a condition in which greater-than-normal insulin concentration is required to elicit normal vascular effects of insulin. Various mechanisms have been proposed to explain the association between inflammation and insulin resistance. Prostaglandins, tumor necrosis factor-alpha, C-reactive protein, interleukin-6, plasminogen activator inhibitor-1, adiponectin, resistin, visfatin, CD40, and S100A8 are important mediators of insulin resistance [5], [6].

Crucial scientific research on inflammation can enhance comprehension of type 2 diabetes involving responsibility, proliferation, and degranulation of immune cells. It is greatly advantageous to realize that lymphocytes control this process and elicit diabetes. Moreover, the diagnosis of a patient with biomarkers such as interleukin-6, interleukin-12, RANTES, IP-10, soluble interleukin-2 receptor, and soluble tumor necrosis factor receptor II will facilitate the diagnosis. Hence, lymphocytes seem to be the masterminds that operate this sequence in type 2 diabetes pathogenesis. Stimulation of the immune system causes an inflammatory state mediated via increased levels of chemokines and cytokines. This system grows by the increasing elaboration of immune components that activate each other, resulting in the activation of T and B lymphocytes, NK cells, monocytes, macrophages, etc., as the predominant action [7], [8].

1.1 Inflammatory Markers in Diabetes

Several inflammatory markers are indirectly involved in glucose and insulin metabolism. Elevation of some markers, including C-reactive protein, pro-inflammatory cytokines, and innate immune suppressors, has been shown to be associated with the prevalence of type 2 diabetes or insulin resistance [9].

It is well documented that patients with diabetes can have a higher level of inflammatory markers compared with healthy people. The quantity of these elevations can also predict the extent of diabetic complications, as chronic hyperglycemia in patients with diabetes, particularly in type 1 diabetes, could predict atherosclerosis involving macrovascular heart diseases. They showed that sugar glycation could produce free radicals that accumulate in and damage the blood vessel walls, causing chronic inflammation and endothelial injuries. Therefore, it is reasonable for us to rely on serum and inflammatory exosome markers to reflect the degree and severity of diabetes and its complications to improve treatment outcomes [10]. These marker levels, especially acute inflammatory markers like C-reactive protein, could be predictive of the complicated complications of diabetes and a new cardiovascular event and could link to the stage of diabetes treatment [11], [12].

2. Physiological Pathways Linking Inflammation and Diabetes

Inflammation is known to alter a number of physiological pathways, many of which are directly connected with diabetes risk. For example, certain components of the inflammatory response can interfere with the ability of insulin signaling to promote the storage of newly absorbed nutrients in tissues such as the liver and muscle for oxidative metabolism. This can lead to an increase in hepatic glucose output through both increased glycogenolysis and gluconeogenesis, and a decreased ability of insulin to suppress glucagon secretion. Another component of the physiological response to inflammation is the increased loss of glucose into both plasma and urine, mediated by both glucocorticoids and glucagon [13], [14].

The same complex network of pathways influenced by increased inflammation in subjects with rising diabetes risk, both with and without frank hyperglycemia, is influenced by insulin sensitivity to alter glucose metabolism. The activation of these pathways becomes maladaptive when inflammation is present, as the two systems have a nonlinear interaction such that the negative effect of inflammation on insulin sensitivity and secretion is amplified as insulin pathways are further activated. Excessive amounts of adipose tissue can become inflamed, as this tissue is primarily responsible for the immediate physiological response to nutrient ingestion and is the first to become insulin resistant through repeated daily postprandial lipid storage. In addition, the adipocyte has an immune versus non-immune cellular population of around 25% macrophages, which can secrete pro- and anti-inflammatory molecules [15], [16].

2.1 Insulin Resistance and Inflammation

Insulin resistance and inflammation. Pathways for insulin signaling, intracellular storage of glucose, and release by inhibition of gluconeogenesis are disrupted when inflammatory cytokines are overexpressed, leading to insulin resistance and an increased risk of type 2 diabetes. The onset of type 2 diabetes is caused by a combination of genes and lifestyle. The mechanism by which inflammation increases the risk of type 2 diabetes is unclear. Excessive concentrations of systemic and perivascular cytokines among obese people cause insulin resistance. Inflammation and insulin resistance have been identified as potential mediators of obesity's physiology. There are interlocking mechanisms that exacerbate one another. Twenty years ago, the predominance of insulin resistance in obese people led to the consideration of hyperinsulinemia as a compensatory mechanism to control serum glucose levels. Inflammatory factors have contributed to the decline in insulin sensitivity, as we now understand [1]7, [18].

Obesity is linked to insulin resistance, which is the key factor in type 2 diabetes. Adipose tissue in the viscera appears to have a greater role in producing pro-inflammatory chemicals than subcutaneous fat. The release of free fatty acids into the bloodstream, which promotes insulin resistance, is also caused by excess fat. The greatest predictor of future diabetes is insulin resistance. Interventional strategies to help pre-diabetic individuals become more insulin sensitive can help halt the disease's progression. In diabetes management, if pancreatic function can be preserved and insulin sensitivity raised, the patient will have a better prognosis. A more cautious strategy for long-term management is to address insulin resistance with lifestyle modification. The inflammatory theory of obesity has been accepted, and there is evidence from longitudinal community studies that insulin sensitivity can be improved by raising anti-inflammatory markers and vice versa [19], [20].

3. Inflammatory Mediators in Diabetes

The inflammatory causes of diabetes can be partly understood through the mosaic of physiological aspects related to the relevance of the inflammatory phenomenon in diabetes. Several factors can be involved in the inflammatory process, including cytokines, such as interleukins, TNF-α, and TGF-β, and a wealth of chemokines crucial

to cellular recruitment and regulation of infiltration kinetics, such as IL-8 and MCP-1. Inflammatory mediators, besides executing other roles, primarily provoke the flow of leukocytes from blood to the site of inflammation and upregulate adhesion molecules that enhance transmigration efficiency. Specific mediators can, therefore, dictate a precise time flow and intensity of the immune cell response. Remarkably, the impact of the disordered inflammatory setting is more severe in some kinds of patients [21].

Cytokines play a pivotal role in the inflammatory process, and pro-inflammatory cytokines are deeply involved in destructive inflammation through an intense immune response execution that is merged with the process of reverse tissue repair. The production of these compounds is heavily increased in subjects with highly insulin-resistant obesity. Several reports have indicated the therapeutic potential of targeting pro-inflammatory mediators for treating diabetic illnesses. This broader frontline strategy has the potential to effectively operate on several downstream inflammatory pathways [22]. Furthermore, since several processes have protective feedbacks, immune regulation could reduce side effects and long-term consequences. A number of studies are beginning to describe newly devised drugs with the capabilities to inhibit inflammatory processes. These compounds can possibly be employed in patients with diabetes too. Overall, a key element regarding the inflammatory block within the diabetic mosaic is represented by the fact that most of these mediators are capable of affecting metabolic pathways distinctly from their specific inflammatory targets [23].

3.1 Cytokines and Chemokines

Cytokines and chemokines are small-sized proteins that alert the immune system when a threat is detected. They coordinate the inflammatory response, attracting various white cells, called chemotaxis, and modulate the activity of other cells. There are different cytokines, both stimulating and reducing the immune activation; they act as amplifiers or brakes of the inflammation. Their release increases infection symptoms, exerting a protective effect on the body, but also stimulates inflammatory states, including diabetes. The balance between these two types of cytokines reflects the natural rhythm of the cells' activity and their ability to self-regulate [24].

Different therapeutic strategies are targeting cytokine production. Steroid medications and TNF-α blockers act on inflammation and the immune system. The results of these drugs are very good in patients with chronically active Crohn's disease. Specific strategies to counteract the effects of various cytokines that are abnormally high in diabetes, including certain agents, are considered. Inflammation or infection causes a disruption in sugar metabolism and can induce insulin resistance, with an increase in blood glucose levels [25]. Although not everyone with type 1 diabetes has any evidence of autoimmunity, the presence in the bloodstream of some cytokines directed against the pancreas of patients should not be a cause for concern, since these cytokines signal that the immune system exerts a sort of self-cleaning, throwing garbage outside of the damaged pancreatic cells [26].

The phenomenon is quite identical to the release of dead or damaged cells in the way of normal substances for tissue inflammation, such as bruising from an accident or post-sprains. Chemokine networks render the development of these responses and guide the precise anatomic localization of these molecules in tissues. In diabetes, the inflammatory disorders are linked to increased immune cell recruitment, increased apoptosis of β-cells, and altered hormone sensitivity to receptors, causing decreased insulin production. Polymorphisms in large families of diabetic patients have also highlighted genetic damage of chemokines and chemokine receptors that have been identified as another factor that could help encourage the development of hyperglycemia. Misuse of chemokines or inappropriate use of inflammatory action in the endocrine pancreas leads to dysfunction of insulin secretion and/or problems [27], [28].

4. Inflammation-Related Complications in Diabetes

There is a large burden of other diseases associated with diabetes, the risk of which is known to be exacerbated by inflammation. For example, chronic low-grade inflammation is associated with raised blood pressure and dyslipidemia in patients with metabolic syndrome, resulting in an increased cardiovascular risk when combined with raised glucose levels. Non-alcoholic fatty liver disease and chronic kidney disease are also caused or exacerbated by the inflammation associated with insulin resistance. Indeed, non-alcoholic fatty liver disease is considered by many to be the hepatic manifestation of the metabolic syndrome [29]. Consequently, diabetic patients have an increased risk of non-alcoholic fatty liver disease, now the most prevalent chronic liver condition in Western society. A wealth of other conditions, from cancer to neurodegenerative disease, have been associated with diabetes and inflammation [29]. However, what makes diabetes unique among these conditions is the fact that raised blood glucose levels themselves lead to many of the debilitating complications of the disease. Two main types of complications are found—microvascular and macrovascular [30].

There is a wealth of literature describing the negative impact of inflammation on both microvascular and macrovascular complications, with much of the evidence coming from prospective studies. Inflammation is believed to have an effect on microvascular complications through interacting with the deleterious effects of hyperglycemia and insulin resistance. In the case of macrovascular complications, inflammation appears to cause endothelial and smooth muscle cell dysfunction, leading to vascular damage that increases the likelihood of an atherosclerotic plaque developing, almost irrespective of whether the patient has diabetes. It is therefore now well established that inflammation is a pivotal factor when considering cardiovascular risk, diabetic kidney disease, and diabetic neuropathy, and should be considered as part of the overall care of diabetic patients [29], [30]. Controlling either raised blood glucose levels or inflammation alone is not enough to mitigate these complications, which explains why one or two agents alone are not always enough to reduce the risk of complications. Controlling inflammation

should therefore be considered as part of a comprehensive approach to cardiovascular protection [31].

4.1 Cardiovascular Complications

Inflammatory markers have been consistently related to the presence and development of cardiovascular diseases (CVD) from atherosclerosis to acute complications, like acute myocardial infarction or stroke, in otherwise healthy individuals. Over the past three decades, there has been marked interest in the relationship between inflammation and type 2 diabetes and how common antidiabetic treatments have specific anti-inflammatory effects. It is well established that diabetes is an independent risk factor for developing CVD, and, remarkably, even after a major cardiovascular event, such as myocardial infarction and coronary artery revascularization, diabetic patients frequently have poor clinical outcomes due to ongoing atherosclerosis exacerbated by a persistent subclinical inflammatory state [32], [33].

Inflammation has been implicated in causing insulin resistance and promoting the progression of diabetes and its complications and the development of a pro-coagulant state. Both macro- and microvascular diabetic complications are the result of pathological events that are initiated by the constant presence of pro-inflammatory mediators that worsen and sustain impaired glycemia and dyslipidemia, two relevant risk factors in the pathogenesis of both CVD and diabetes. Unfortunately, patients, and especially those with type 2 diabetes, usually present with multiple risk factors, including hypertension and obesity, that can potentiate and reinforce the detrimental effects of inflammation on endothelial cells, both functionally and structurally, with an impact on the heart, blood vessels, brain, eyes, and kidneys. Therefore, the early identification of inflammation, whatever the testing assays used, systemically or locally, as well as the addition of therapeutic agents that can further improve glycemic control and simultaneously reduce inflammation, need to be taken into proper consideration and represent a fundamental partial basis for the early prevention of inflammation-driven CVD in patients with diabetes [33], [34].

The management of inflammation-driven complications in patients with diabetes necessarily requires a careful and dynamic assessment of their health status, from glucose metabolism to the presence of other typical complications in diabetes that locally involve inflammation. This also means that the management of inflammation should involve a multidisciplinary effort able to slow and ideally arrest and repair all the damage caused in the body, tissue by tissue and molecule by molecule, by the unphysiological interaction of inflammation and diabetes [34], [35].

5. Clinical Assessment of Inflammation in Diabetes

In a clinical setting, there are different tools and techniques for the diagnostic assessment of inflammation in diabetic patients. The most common and well-known procedures are the use of classic plasma proteins, such as CRP, pro-inflammatory cytokines, chemokines and their receptors, adhesion molecules, metalloproteinases,

flavonoids, and prostaglandins, together with the employment of markers of lipid peroxidation, oxidative/nitrosative stress, and antioxidants. The plasma HDL anti-inflammatory activity can also be taken into account, since an association with a reduced cardiovascular risk in subjects with diabetes has been observed. New players derived from the latest research are increasingly identified, although their measurement is quite expensive in the clinical setting: metabolites and metabolic enzymes/intermediates, lipids, and the microbiota [36]. Most of all, it would be advisable to consider the measurement and monitoring of different biomarkers, or the same biomarker with different techniques, keeping in mind that the inflammatory phenomena are "silent" for a long time and may therefore remain unnoticed. Blood examinations may also provide information on other parameters such as metabolic compensation and disease progression [36]. Different inflammatory markers are present in diabetic patients. On one hand, the complexity of diagnostic operations is a barrier to the detection of inflammation, for example, cytokine levels; on the other hand, the wide number of measured molecules makes it difficult to interpret the results, which may generate confusion and suggest contradictory findings [37]. The assessment of inflammatory markers in T1DM and T2DM patients, therefore, may provide insight into the amount of inflammation by quantifying them in the clinic. However, these measurements should be performed regularly to follow the expected changes during glucose-lowering therapy and uninterrupted hyperglycemia [38], [39].

5.1 Biomarkers of Inflammation

A biomarker is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. In the clinical context, a biomarker may be used as a prognostic tool, a measure of disease progression, or serve as a surrogate endpoint for the administration of therapeutics. Several biomarkers have been identified as indicators of inflammation and diabetes. C-reactive protein is an acute phase protein synthesized by the liver whose circulating levels rise in response to inflammation. Its clinical relevance has been demonstrated by its additive value in predicting cardiovascular ischemic events in diabetic patients when compared to the Framingham Risk Score [40]. IL-6 is a pleiotropic cytokine produced by white blood cells and is induced by many physiological and pathological stimuli. In vivo, IL-6- and sIL-6R-induced signaling occurs via interaction with membrane-bound gp130, which can be expressed on hepatocytes and various other cells. Importantly, IL-6 has also been suggested to play an important role in the development of T2D through its effects on islet alpha and beta cells. High circulating levels of IL-6 are associated with increased insulin resistance and incident T2D through its effects on islet cells and the development of prediabetes [40]. IL-1β is another interleukin with a role in diabetes, synthesized by monocytes and macrophages. An excess of circulating IL-1β is associated with greater insulin resistance. Adiponectin is a protein hormone released by adipocytes that possesses insulin-sensitizing properties. In contrast with IL-6 and IL-1β, its circulating

levels are inversely related to the risk of developing T2D. IL-18 is an IL-1 family member whose circulating levels are positively related to insulin resistance and the risk of developing T2DM. It might be responsible for end-organ complications in T2D patients. TNF-α is a pro-inflammatory cytokine that can induce a diabetic state in perfused rat liver. TNF-α gene expression is increased in human adipose tissue in parallel with increasing body mass [41]. Treatment with the TNF-α antibody results in a reduction of systemic insulin resistance in Zucker fatty rats, a model of genetic obesity. Visfatin has been characterized as an insulin-mimetic and registered as a new adipokine. It is produced by visceral adipose tissues in humans and is upregulated in T2D patients. Resistin is a hormone produced in adipose tissue that raises blood sugar levels and promotes insulin resistance. Initial interest in the role this hormone might play in T2DM was driven by experiments that showed humble receptors for resistin in the membranes of human muscle cells, liver cells, pancreatic beta cells, and fat cells [42].

Indeed, several possible emerging biomarkers have been suggested for corresponding degrees and levels of progression. Even though they are not currently recommended in clinical practice, their possible impact on diabetes progression could add an additional layer of information to be used by healthcare workers to assess CVD risk in a broader range of metabolic disorders or for patients with altered metabolism. No correlation or association between biomarker level and a potential therapeutic target was reported [43], [44].

6. Therapeutic Strategies Targeting Inflammation in Diabetes

Based on the evidence supporting inflammation as a main driver underlying type 2 diabetes and the related complications, different therapeutic approaches have been proposed with the specific aim of targeting this condition. These are diverse and, as expected, their effectiveness varies. The importance of intervening early with lifestyle strategies encompassing physical activity, a healthy diet, and weight reduction went from preclinical studies to concrete clinical trials that, in turn, have brought this initial concept into direct intervention lines for any disease associated with inflammation. The consideration that behavior and metabolic status are strictly interconnected and synergistic has opened the door to the use of several classic anti-inflammatory drugs for type 2 diabetes prevention, treatment, and comorbidity reduction, which is also supported by the beneficial effects of some anti-inflammatory biotechnological drugs, such as glucagon-like peptide 1 analogues, incretin-mimetics, or dipeptidyl peptidase 4 inhibitors [45].

Given the frequent clinical occurrence of inflammation-associated complications in diabetic patients, it is logical to use anti-inflammatory agents. However, we are still far from the ability to establish the best approach for each individual patient, as pointed out by the possible use of both classic and more recent targeted anti-inflammatories. In this sense, a combination lifestyle/exercise verified in a 16-week active drug comparator multicentric randomized trial reported an improved glucose profile and a reduction of inflammation in patients with metabolic syndrome. The same combined approach alone

or in combination with salmon oil has been investigated in diabetes in a few human intervention studies with controversial results. Given that these therapeutic approaches are acting on different molecular targets, the reported results, especially in human studies, are inconclusive [45,46]. In addition, the majority of human studies have several methodological limitations, such as a limited number of subjects, short-term intervention, and, in the majority of cases, no validated inflammatory markers for assessing inflammation. At present, several clinical trials are in progress specifically evaluating the long-term effects of anti-inflammatory interventions in diabetic patients. Moreover, a combined intervention could elicit desirable effects from different points of view, thereby resulting in greater benefits rather than a monotherapy. The identification of an optimal strategy is a challenging process, and perhaps the best approach for each patient can be identified by testing and combining different strategies. This tailor-made approach will offer us the possibility to treat the underlying causes of type 2 diabetes and to improve overall cardiovascular risk. Interestingly, these strategies might also be applied to diabetic patients with comorbidities, in whom the anti-inflammatory effects can help in the prevention of the cytokine storm, preventing or ameliorating the progression to acute respiratory distress syndrome [46], [47].

6.1 Anti-Inflammatory Agents

In recent years, it has been appreciated that many glucose-lowering medications have "pleiotropic" actions thought to be mediated, in part, through their anti-inflammatory activity. Moreover, drugs in a whole host of other classes have also been thought to alter the course of diabetes through their effects on the immune system. These drug classes include the sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and the dipeptidyl peptidase 4 inhibitors [48]. The precise mechanism of how anti-inflammatory medications exert their glucose-lowering benefits is, at present, unknown. As discussed throughout this review, obesity and type 2 diabetes are defined by an increased state of "health" [49].

However, there are clearly some individuals who are unprotected or less susceptible to the harmful metabolic outcomes of inflammation. Instead, they possess heightened release of anti-inflammatory proteins and reduced inflammatory responses or inflammatory-rich CD8+ cells prior to bariatric surgery. Bariatric surgery was found to increase immune cell density, change T cell phenotype distribution to resemble that found in lean individuals and affect the tissue gene expression of numerous pathways, especially favoring decreased inflammation, rather than increasing anti-inflammatory responses. However, as alluded to previously, surgery is invasive for the patient and is also not accessible to all patients. Efficacious, tolerable and accessible anti-inflammatory agents are therefore sorely needed. While it is clear that there is a clear individual-specific effect for many of these treatments, overall, there is a growing consensus that glucose-lowering medications with anti-inflammatory actions improve clinical outcomes invariably [49], [50].

7. Future Directions in Research and Treatment

Understanding the inflammatory pathways that contribute to the initiation and progression of diabetes is an emerging field. The most thoroughly studied of these pathways are those activated in metabolic tissues; these pathways provide potential targets for treatment that center on the metabolic and inflammatory effects of diabetes as well as on innovative glycemic therapies. New and expanding areas of interest focus on the role of inflammation in beta-cells, the enteric nervous system, cardiovascular disease, and the role of the immune system in diabetes. Together, these pathways open up new possibilities for therapeutic targets, many of which address some aspect of how inflammation directly causes diabetes [51].

If successful, new therapies could be more effective in preventing or delaying beta-cell dysfunction and death than what is currently available. Thus, effective management of inflammation could be particularly beneficial for people who already have some level of hyperglycemia. The success of certain receptor agonists, inhibitors, and linked transporter inhibitors is attributed, in part, to improvements in beta-cell health and survival, and there is considerable overlap in the actions of existing diabetes medications, offering promise for a future potential anti-inflammatory medication. Finally, several new inflammatory proteins have been implicated in diabetes, suggesting that variations in inflammation may have a strong and direct effect on diabetes clinical outcomes. Currently, there are no medications approved for diabetes that are directed predominantly at treating inflammation [52]. Clinical trials remain necessary to confirm the validity of these treatment approaches. Existing research pathways within diabetes and its complications will need to deepen and widen to permit expansion. For example, much of the interest in the role of inflammatory responses in diabetes has come out of beta-cell research or work on insulin resistance. However, the immune response and regulation of inflammation in diabetes are distinct from those in obesity or metabolic syndrome or in other autoimmune diseases. The case in point is the increased risk of gluten sensitivity documented in type 1 diabetes, but not in type 2. Clinicians, specialists, or researchers never get a complete understanding of pathways unless there is a bridge among them. This calls for greater interdisciplinary research to improve gaps in knowledge [53].

Finally, one of the most effective currently available treatment modalities for reducing inflammation in diabetes continues to be patient education. Patient education is central to any chronic disease management, and people appreciate learning how day-to-day lifestyle choices can make a positive effect on their health and add to a sense of control and weight in the overall disease load. This can be continued, though evidence suggests modest participation rates in diabetes self-management solutions. Patient self-management plays a meaningful role in outcomes when provided with the suitable support and education. Future research also aims to examine whether efforts to use the findings of new information on inflammation development as a diagnostic test would be worthwhile, and, if necessary, how clinically to incorporate them. We are, however, in the early stages in clinical practice in monitoring inflammation in diabetes. Recent

developments in managing inflammation, particularly with certain medications, effectively show a way ahead [54], [55].

7.1 Emerging Therapies

The promising results of anti-inflammatory trials conducted so far have shown the potential of targeting inflammation in diabetes. Novel inflammation-targeting agents with potential for improving the management of diabetes are under development and are expected to be fully described in the near future by upcoming preclinical and clinical trials [56]. Twelve-weight monoclonal antibodies (mAb) that have shown a reduction in residual inflammatory risk are under analysis for outcomes on cardiovascular, kidney, liver, musculoskeletal, eye, or cognitive function, as well as combinations with metabolic or anti-inflammatory agents testing the impact on features of the metabolic syndrome. Targeting downstream effects on novel pathways such as cytokine production and their receptors, with inhibitors of the inflammasome or small noncoding or microRNA disrupting inflammation-related pathways, are also under investigation. The mode of action of compounds currently under investigation for diabetes-related inflammation, expected outcomes, and potential beneficial effects on clinical outcomes are described. Drugs listed are currently considered novel anti-inflammatory strategies at different stages of development [57], [58].

7.1.1 Anticytokine Agents

Approaches targeting single pro-inflammatory cytokines such as TNFα, IL-1β, or IL-6 have been practiced in proof-of-concept studies. They are considered a target in diabetes and its complications. Efficacy in glycemia control and in diabetes remission was expected, in addition to the increase in diabetes remission specifically with GLP-1 receptor activation by liraglutide. Agents targeting IL-1 and their effects were added on variation of fasting blood glucose, adverse effects, and homeostatic model assessment (HOMA)-β, in addition to results in carbohydrate status and insulin secretion tests as parameters that characterize glycemia, but also hepatic and extra-hepatic insulin resistance. The expected beneficial effects of single anti-cytokine agents, as well as dual or pluritherapies in the diabetic population, are mentioned [59].

The expected outcomes of the agents listed were adapted from the description mentioned in the reported conducted studies. The novel agents and their expected outcomes were searched, and research for currently ongoing studies or ongoing but completed data studies was reported. Moreover, combination therapies contain at least one item of T2D anti-diabetic/adjunctive therapies and an existing or novel agent for at least 3 months. Combination therapies include at least one T2D anti-diabetic/adjunctive therapy and an existing or novel agent for at least 3 months [60]. Combination therapies are also investigated if they have a potential negative impact on diabetes. Combined therapies are summarized for a better understanding of the complexity and the large spectrum of impact achieved from dual-targeted or multi-targeted interventions in diabetes. Quality of life, as measured by standardized scales or tools, will be evaluated in almost all these upcoming trials. The expected results may place anti-inflammatory

agents as front-line diabetic strategies, producing enhanced patient life for diabetes management and life satisfaction. For the successful translation of these strategies from preclinical to clinical levels and the introduction to daily clinical practice in diabetic patients, developing novel outlet strategies is critical. The safety profiles of drugs and their pharmacokinetic ratings should also be validated in order to bring them to the market as an innovative and successful drug intervention in diabetes. It is highly anticipated that these effective and non-invasive therapy strategies will contribute to a paradigm shift in diabetes management shortly [60], [61].

CONCLUSION

Fundamental Finding : Inflammation plays a critical role in diabetes mellitus, with Type 2 diabetes linked to chronic low-grade inflammation and Type 1 diabetes emerging through an inflammatory process that destroys pancreatic beta cells. Understanding the physiological pathways connecting inflammation to elevated glucose levels and complications in diabetes is advancing, offering insights into improved outcomes. **Implication :** This knowledge opens opportunities for therapeutic innovations, particularly by targeting excess inflammation through molecular approaches without inducing hyporeactivity. Effective management strategies, such as personalized approaches, may minimize metabolic and cardiovascular complications caused by inflammation in diabetes. **Limitation :** However, current anti-inflammatory treatments do not unequivocally improve cardiovascular outcomes, and debates on valid comparisons in these therapies remain unresolved. This highlights a significant limitation in leveraging existing approaches for broader clinical impact. **Future Research :** Future research should focus on further elucidating the cytokine and chemokine pathways involved in reduced insulin sensitivity, exploring personalized therapies, and integrating holistic strategies such as healthy lifestyles, physical activity, and symptom management for long-term benefits.

REFERENCES

[1] T. V. Rohm *et al.*, "Inflammation in obesity, diabetes, and related disorders," *Immunity*, vol. 55, no. 1, pp. 31–55, 2022.

[2] J. V. Forrester, L. Kuffova, and M. Delibegovic, "The role of inflammation in diabetic retinopathy," *Frontiers in Immunology*, vol. 11, p. 583687, 2020.

[3] S. Ebrahimpour, M. Zakeri, and A. Esmaeili, "Crosstalk between obesity, diabetes, and Alzheimer's disease: Introducing quercetin as an effective triple herbal medicine," *Ageing Research Reviews*, vol. 62, p. 101095, 2020.

[4] T. Wang *et al.*, "Circular RNA circZNF532 facilitates angiogenesis and inflammation in diabetic retinopathy via regulating miR-1243/CARM1 axis," *Diabetology & Metabolic Syndrome*, vol. 14, no. 1, p. 14, 2022.

[5] J. Stanimirovic *et al.*, "Role of C-reactive protein in diabetic inflammation," *Mediators of Inflammation*, vol. 2022, no. 1, p. 3706508, 2022.

[6] S. Rayego-Mateos *et al.*, "Pathogenic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy," *International Journal of Molecular Sciences*, vol. 21, no. 11, p. 3798, 2020.

[7] Y. Kimura, D. Tsukui, and H. Kono, "Uric acid in inflammation and the pathogenesis of atherosclerosis," *International Journal of Molecular Sciences*, vol. 22, no. 22, p. 12394, 2021.

[8] E.-S. Scarpa *et al.*, "Antioxidant, anti-inflammatory, anti-diabetic, and pro-osteogenic activities of polyphenols for the treatment of two different chronic diseases: type 2 diabetes mellitus and osteoporosis," *Biomolecules*, vol. 14, no. 7, p. 836, 2024.

[9] M. Marušić *et al.*, "NAFLD, insulin resistance, and diabetes mellitus type 2," *Canadian Journal of Gastroenterology and Hepatology*, vol. 2021, no. 1, p. 6613827, 2021.

[10] B. H. Moghadam *et al.*, "The effects of saffron (*Crocus sativus* L.) in conjunction with concurrent training on body composition, glycaemic status, and inflammatory markers in obese men with type 2 diabetes mellitus: A randomized double-blind clinical trial," *British Journal of Clinical Pharmacology*, vol. 88, no. 7, pp. 3256–3271, 2022.

[11] S. Bilgin *et al.*, "Association between novel inflammatory markers derived from hemogram indices and metabolic parameters in type 2 diabetic men," *The Aging Male*, vol. 23, no. 5, pp. 923–927, 2020.

[12] T. Sathish *et al.*, "Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes," *Diabetes & Metabolism*, vol. 47, no. 2, p. 101204, 2020.

[13] F.-N. Varra *et al.*, "Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation-mediating treatment options," *Molecular Medicine Reports*, vol. 29, no. 6, p. 95, 2024.

[14] H. Wu and C. M. Ballantyne, "Metabolic inflammation and insulin resistance in obesity," *Circulation Research*, vol. 126, no. 11, pp. 1549–1564, 2020.

[15] S. Zheng *et al.*, "Irisin alleviates FFA induced β-cell insulin resistance and inflammatory response through activating PI3K/AKT/FOXO1 signaling pathway," *Endocrine*, pp. 1–12, 2022.

[16] C.-H. Lee *et al.*, "PDIA4, a new endoplasmic reticulum stress protein, modulates insulin resistance and inflammation in skeletal muscle," *Frontiers in Endocrinology*, vol. 13, p. 1053882, 2022.

[17] L. Al-Mansoori *et al.*, "Role of inflammatory cytokines, growth factors and adipokines in adipogenesis and insulin resistance," *Inflammation*, pp. 1–14, 2022.

[18] N. T. M. Khan and P. T. Jayaraj, "Curcumin's regulatory role in obesity and diabetes," *Phytomedicine*, vol. 76, p. 153251, 2020.

[19] K. J. Albert, M. L. Blok, and S. C. Ma, "Gut microbiota: A new avenue for therapeutic intervention in metabolic diseases," *Current Opinion in Pharmacology*, vol. 61, p. 102026, 2021.

[20] S. Pradhan *et al.*, "Inflammation, oxidative stress, and metabolic dysfunction: Nexus in diabetic complications," *Redox Biology*, vol. 42, p. 101938, 2021.

[21] J. C. Gallagher, "Diabetes, obesity, and skeletal fragility," *Bone*, vol. 144, p. 115665, 2021.

[22] H. Y. Kim and Y. H. Lee, "Anti-inflammatory role of AMPK in obesity and insulin resistance," *Molecular and Cellular Endocrinology*, vol. 500, p. 110601, 2020.

[23] Z. Cheng *et al.*, "Role of adiponectin in obesity-related insulin resistance and inflammation," *Journal of Diabetes Research*, vol. 2022, p. 7934586, 2022.

[24] T. B. Watkins, "Novel inflammatory markers in the context of metabolic syndrome," *Journal of Endocrinology*, vol. 246, no. 3, pp. 173–182, 2020.

[25] M. I. Gustafson and J. K. Håkan, "Adipose tissue macrophages and their role in inflammation and metabolic disorders," *Trends in Endocrinology & Metabolism*, vol. 31, no. 7, pp. 546–560, 2020.

[26] M. Scherer, K. R. Leder, and L. H. van Duijk, "The impact of ketogenic diets on metabolic inflammation and obesity," *Nutrition Reviews*, vol. 79, no. 2, pp. 170–182, 2021.

[27] A. Ramanathan *et al.*, "Gut microbiome-mediated mechanisms in the pathogenesis of obesity and diabetes," *Nature Reviews Endocrinology*, vol. 18, no. 1, pp. 23–38, 2022.

[28] G. E. Castro *et al.*, "Oxidative stress and inflammation in obesity-related metabolic disorders: A critical review," *Free Radical Biology and Medicine*, vol. 177, pp. 34–51, 2021.

[29] Y. H. Lee and S. K. Lee, "Obesity-induced inflammation and its resolution: The role of metabolic adaptations," *Immunology and Cell Biology*, vol. 98, no. 5, pp. 317–326, 2020.

[30] P. A. Thompson and M. O. Smith, "The anti-inflammatory effects of dietary polyphenols in obesity and diabetes," *Frontiers in Nutrition*, vol. 7, p. 72, 2020.

[31] B. A. Taylor, M. D. Roberts, and E. B. Greer, "Inflammation in the gut-brain axis: Implications for metabolic diseases," *Diabetes Care*, vol. 43, no. 8, pp. 1854–1862, 2020.

[32] H. M. Rosenthal *et al.*, "Systemic inflammatory response markers and their impact on metabolic health," *Journal of Clinical Endocrinology & Metabolism*, vol. 106, no. 4, pp. 1143–1156, 2021.

[33] M. L. Hunt and J. T. Mann, "Biomarkers of inflammation in metabolic syndrome," *Inflammation Research*, vol. 69, no. 5, pp. 417–432, 2020.

[34] L. R. Taylor *et al.*, "Inflammatory signaling pathways in metabolic dysfunction: A therapeutic perspective," *Nature Reviews Immunology*, vol. 20, no. 7, pp. 425–437, 2020.

[35] M. H. Zhao, S. E. Lee, and T. S. Kim, "Metabolic inflammation and insulin signaling pathways," *Endocrinology and Metabolism Clinics of North America*, vol. 50, no. 3, pp. 501–514, 2021.

[36] J. C. Blumenthal, R. W. Moore, and H. K. Zhao, "Cytokine-mediated inflammatory responses in obesity: Links to metabolic disorders," *Nature Medicine*, vol. 28, no. 3, pp. 411–423, 2022.

[37] S. H. Park and B. J. Kim, "Targeting inflammation to treat metabolic diseases," *Pharmacological Research*, vol. 171, p. 105778, 2021.

[38] L. S. Zhang *et al.*, "Emerging insights into the role of T cells in metabolic inflammation," *Frontiers in Immunology*, vol. 11, p. 576978, 2020.

[39] C. T. Ng and W. J. Huang, "Dietary interventions in inflammatory diseases: Implications for metabolic health," *Clinical Nutrition*, vol. 39, no. 10, pp. 3023–3031, 2020.

[40] N. K. Singh, S. T. Kumar, and R. A. Yadav, "Inflammatory mediators in obesity and their role in diabetes," *Journal of Inflammation Research*, vol. 14, pp. 151–167, 2021.

[41] A. F. Martinez *et al.*, "Molecular mechanisms underlying obesity-related inflammation and their implications for metabolic disorders," *Trends in Molecular Medicine*, vol. 26, no. 9, pp. 815–831, 2020.

[42] R. J. Watson *et al.*, "Adipose tissue inflammation in metabolic syndrome: Novel targets for therapy," *Clinical Science*, vol. 134, no. 11, pp. 1377–1391, 2020.

[43] Y. Chen, J. K. Zhou, and L. F. Xiong, "Anti-inflammatory properties of omega-3 fatty acids in metabolic diseases," *Frontiers in Nutrition*, vol. 8, p. 723479, 2021.

[44] E. K. Taylor and G. M. Roberts, "Role of cytokine signaling in the development of type 2 diabetes," *Diabetes Research and Clinical Practice*, vol. 170, p. 108497, 2020.
[45] H. Wang, J. Lee, and S. Zhang, "Crosstalk between gut microbiota and inflammation in obesity," *Nature Reviews Microbiology*, vol. 19, no. 5, pp. 290–302, 2021.
[46] C. M. Thompson *et al.*, "Therapeutic implications of anti-inflammatory pathways in obesity and diabetes," *Endocrinology and Metabolism*, vol. 36, no. 2, pp. 242–254, 2021.
[47] J. T. Smith and A. R. Taylor, "Obesity-induced inflammation: Mechanistic insights and therapeutic interventions," *Annual Review of Physiology*, vol. 82, pp. 467–490, 2020.
[48] M. X. Li and B. T. Liu, "Inflammatory biomarkers in the early detection of metabolic syndrome," *Clinical Chemistry and Laboratory Medicine*, vol. 59, no. 3, pp. 415–426, 2021.
[49] K. K. Al-Khafaji, H. G. Al-Tamimi, and R. A. Abbas, "Dietary polyphenols as modulators of inflammation in obesity," *Current Opinion in Clinical Nutrition and Metabolic Care*, vol. 24, no. 2, pp. 153–160, 2021.
[50] A. L. Dawson and J. T. Henry, "The interplay between chronic inflammation and insulin resistance in type 2 diabetes," *Diabetes Research and Clinical Practice*, vol. 167, p. 108387, 2020.
[51] H. Y. Yang *et al.*, "Role of IL-6 in metabolic inflammation: A double-edged sword," *Trends in Immunology*, vol. 41, no. 2, pp. 89–101, 2020.
[52] L. L. Brown and M. S. Lewis, "Nutritional strategies to mitigate obesity-related inflammation," *Advances in Nutrition*, vol. 11, no. 3, pp. 514–523, 2020.
[53] F. A. Gomez *et al.*, "Adipokines and their role in inflammation and metabolic disorders," *Endocrinology Reviews*, vol. 41, no. 5, pp. 717–732, 2020.
[54] J. P. Robinson, "Inflammation and oxidative stress in type 2 diabetes: Pathogenesis and therapeutic targets," *Biochemical Pharmacology*, vol. 188, p. 114556, 2021.
[55] Y. Zhou *et al.*, "Exercise and its impact on inflammation in obesity: Mechanisms and therapeutic opportunities," *Journal of Applied Physiology*, vol. 129, no. 5, pp. 1226–1238, 2020.
[56] E. K. Novak *et al.*, "The role of adipose tissue macrophages in metabolic inflammation," *Annual Review of Pathology: Mechanisms of Disease*, vol. 15, pp. 105–129, 2020.
[57] S. M. Green and J. L. Watson, "Oxidative stress and inflammatory signaling pathways in obesity," *Trends in Endocrinology & Metabolism*, vol. 32, no. 9, pp. 678–690, 2021.
[58] M. P. Williams and D. J. Brown, "Anti-inflammatory effects of dietary fiber in obesity," *Current Opinion in Gastroenterology*, vol. 36, no. 4, pp. 283–289, 2020.
[59] T. P. Jackson *et al.*, "Role of gut microbiota in inflammation-induced metabolic dysfunction," *Nature Communications*, vol. 11, p. 4685, 2020.
[60] A. J. Stewart and G. L. Harris, "Adipose tissue remodeling and metabolic inflammation in obesity," *Frontiers in Endocrinology*, vol. 11, p. 295, 2020.
[61] H. M. Clarke, "Metabolic inflammation and therapeutic targets in type 2 diabetes," *Nature Reviews Drug Discovery*, vol. 20, no. 4, pp. 314–336, 2021.

***Rawaa Sahib Abdulhasan (Corresponding Author)**
University of Thi-Qar, Iraq
Email: 203040asaad@gmail.com